Objective: To analyze the benefits of treatment with Recombinant Human Leptin in areas presenting Lipodystrophy and its impacts on serum levels of Glycemia and Glycated Hemoglobin. Methods: This is an integrative review, in which data collection was conducted in the PubMed database. Twelve articles were selected from the period 2002 to 2020. Results: Treatment of Lipodystrophy through Recombinant Human Leptin has been studied over the years to prevent and delay the onset of this alteration. Leptin replacement is performed in individuals with Lipodystrophy. Administration of this hormone attenuated hypoleptinemia, and consequently moderated adipose tissue degradation and glycemic control, resulting in improved insulin resistance. Conclusion: It is concluded that treatment with leptin directly influences the improvement of clinical and laboratory signs of Lipodystrophy, preventing rapid progression of adipose tissue degradation and glycemic imbalance, as well as reducing levels of Glycated Hemoglobin.
No takes yet. Share an insight, caveat, or question.
Castro et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: